IceCure Applauds ASBrS for Including Cryoablation in Breast Cancer Guidelines
IceCure Medical Ltd. has recently announced a significant milestone in the treatment of breast cancer. The American Society of Breast Surgeons (ASBrS) is finalizing an updated guide that includes cryoablation as a viable treatment option for low-risk breast cancer patients. This update is crucial as it is anticipated to lead to an increase in the recommendation of cryoablation procedures by breast surgeons, aligning with recent FDA marketing authorization granted in October 2025.
The proposed resource guide titled "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast" outlines that cryoablation can be a preferred option for patients aged 70 and above, especially those treated with adjuvant endocrine therapy. This step is particularly beneficial for patients who are not eligible for surgical interventions, thus representing a shift towards more inclusive care options in breast cancer treatment.
Eyal Shamir, CEO of IceCure Medical, expressed his optimism regarding the ASBrS's decision to embrace cryoablation, saying, "The proposed update to the ASBrS treatment guidelines represents an important step forward for breast cancer care." With cryoablation recognized as a minimally invasive treatment method that destroys tumors by freezing, it presents a significant alternative to traditional surgical approaches.
This proposed update follows a recently concluded comment period, inviting insights from medical professionals regarding the inclusion of cryoablation in the guidelines. The feedback received reflects a growing body of clinical evidence from various studies, including IceCure’s own ICE3 trial. This study demonstrated a local recurrence rate of just 3.1% within five years for patients treated with hormone therapy and cryoablation, suggesting its comparable efficacy to lumpectomy.
The potential benefits of cryoablation cannot be overstated. Patients may experience quicker recovery times and less pain and risk than traditional surgical options, making this an attractive alternative for many individuals facing breast cancer treatment decisions. The ProSense® Cryoablation System is at the forefront of this advancement and is specifically designed to effectively treat low-risk breast tumors with minimal invasiveness.
Moreover, the cryoablation technique is gaining traction across North America, with recent installations of IceCure's systems at prestigious medical institutions, highlighting increased clinical interest following FDA clearance. The ProSense® system is expected to cater to approximately 200,000 women annually, including those with early-stage, low-risk breast cancer and patients with benign tumors such as fibroadenomas.
IceCure Medical, known for its pioneering role in developing cryoablation technology, remains dedicated to enhancing patient care through innovative options that prioritize safety and efficiency. By positioning cryoablation alongside established treatments in medical guidelines, IceCure hopes to pave the way for its widespread adoption, thus improving patient outcomes and overall satisfaction.
In conclusion, the endorsement of cryoablation by the ASBrS marks a monumental step in the evolution of breast cancer treatments. As IceCure Medical prepares for the next phase of commercial development and stakeholder engagement, there is a sense of optimism surrounding the future of breast cancer care. The anticipated changes in guidelines create an opportunity for more patients to access guided and effective therapies that align with their individual health needs.
The proposed resource guide titled "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast" outlines that cryoablation can be a preferred option for patients aged 70 and above, especially those treated with adjuvant endocrine therapy. This step is particularly beneficial for patients who are not eligible for surgical interventions, thus representing a shift towards more inclusive care options in breast cancer treatment.
Eyal Shamir, CEO of IceCure Medical, expressed his optimism regarding the ASBrS's decision to embrace cryoablation, saying, "The proposed update to the ASBrS treatment guidelines represents an important step forward for breast cancer care." With cryoablation recognized as a minimally invasive treatment method that destroys tumors by freezing, it presents a significant alternative to traditional surgical approaches.
This proposed update follows a recently concluded comment period, inviting insights from medical professionals regarding the inclusion of cryoablation in the guidelines. The feedback received reflects a growing body of clinical evidence from various studies, including IceCure’s own ICE3 trial. This study demonstrated a local recurrence rate of just 3.1% within five years for patients treated with hormone therapy and cryoablation, suggesting its comparable efficacy to lumpectomy.
The potential benefits of cryoablation cannot be overstated. Patients may experience quicker recovery times and less pain and risk than traditional surgical options, making this an attractive alternative for many individuals facing breast cancer treatment decisions. The ProSense® Cryoablation System is at the forefront of this advancement and is specifically designed to effectively treat low-risk breast tumors with minimal invasiveness.
Moreover, the cryoablation technique is gaining traction across North America, with recent installations of IceCure's systems at prestigious medical institutions, highlighting increased clinical interest following FDA clearance. The ProSense® system is expected to cater to approximately 200,000 women annually, including those with early-stage, low-risk breast cancer and patients with benign tumors such as fibroadenomas.
IceCure Medical, known for its pioneering role in developing cryoablation technology, remains dedicated to enhancing patient care through innovative options that prioritize safety and efficiency. By positioning cryoablation alongside established treatments in medical guidelines, IceCure hopes to pave the way for its widespread adoption, thus improving patient outcomes and overall satisfaction.
In conclusion, the endorsement of cryoablation by the ASBrS marks a monumental step in the evolution of breast cancer treatments. As IceCure Medical prepares for the next phase of commercial development and stakeholder engagement, there is a sense of optimism surrounding the future of breast cancer care. The anticipated changes in guidelines create an opportunity for more patients to access guided and effective therapies that align with their individual health needs.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.